^
Association details:
Biomarker:No biomarker
Cancer:Chronic Lymphocytic Leukemia
Drug:Gazyva (obinutuzumab) (CD20 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/22/2014
Excerpt:
Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
Secondary therapy:
chlorambucil
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody indicated:...in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Secondary therapy:
chlorambucil
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
08/30/2022
Excerpt:
The following regimens are included as options for relapsed/refractory disease regardless of patient’s age or comorbidities...HDMP + rituximab or obinutuzumab (category 2B)
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma: Useful in Certain Circumstances…Obinutuzumab ± chlorambucil...
Secondary therapy:
chlorambucil
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

Excerpt:
...overall response rates at three months post treatment exceeded 80% for all obinutuzumab-chemotherapy combinations.
Secondary therapy:
Chemotherapy
DOI:
10.3324/haematol.2017.186387
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

Excerpt:
...CLL patients who received obinutuzumab plus fludarabine and cyclophosphamide (G-FC)...Overall response rate was observed in 90.0%, with 46.4% of patients achieving complete response...Frontline G-FC represents a promising treatment option for fit patients with CLL.
Secondary therapy:
cyclophosphamide + fludarabine oral
Trial ID: